NCT04238169View on ClinicalTrials.gov

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions
Non-Small-Cell Lung Cancer Stage IV
Interventions
DRUG

Bevacizumab

7.5mg/kg once every three weeks

DRUG

Toripalimab

240 mg once every three weeks

RADIATION

SBRT

30-50Gy/5F（2-4 lesions）

Trial Locations (1)

400000

Xinqiao Hospital of Chongqing, Chongqing

All Listed Sponsors
lead

Xinqiao Hospital of Chongqing

OTHER

NCT04238169 - Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | Biotech Hunter | Biotech Hunter